National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Understanding Cancer Series: Angiogenesis
< Back to Main
In English     En español
    Posted: 01/28/2005    Reviewed: 09/01/2006
Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
View/Print PowerPoint
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Slide 16  :  Angiogenesis Inhibitors and Primary Tumors <  >  

The discovery of angiogenesis inhibitors raises the question of whether such molecules might therapeutically halt or restrain cancer's growth. Researchers have addressed this question in numerous experiments involving animals. In one striking study, mice with several different kinds of cancer were treated with injections of endostatin. After a few cycles of treatment, the initial (primary) tumor formed at the site of the injected cancer cells almost disappeared, and the animals did not develop resistance to the effects of endostatin after repeated usage.

Angiogenesis Inhibitors and Primary Tumors

< Previous  |  Index  |  Next Slide >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov